Malignant colorectal or melanoma cancer at the international cancer congress ASCO 2012 in Chicago.

Antisense Pharma presents data from trabedersen Stage I/II cancer study at ASCO 2012 The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant colorectal or melanoma cancer at the international cancer congress ASCO 2012 in Chicago, USA .e. Suppression of antitumor immune response and metastasis read more . ‘Trabedersen shows excellent safety and encouraging survival outcomes in sufferers with advanced solid tumors’, concludes Dr. Hubert Heinrichs, Chief Medical Officer at Antisense Pharma. ‘In comparison to current remedies for late stage pancreatic carcinoma or malignant melanoma, our compound may prove to be an extremely novel and appealing therapeutic alternative.’..

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise Antisense Therapeutics Ltd. has reported further excellent results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancers. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive aftereffect of the cancer drug Paclitaxel. Paclitaxel is one of a class of medicines known as taxanes. Along with androgen blockade, taxane chemotherapy can be an important treatment choice in the most harmful form of the disease, castration-resistant prostate cancers . Illustrating the positive effects of the medication in this mouse style of prostate malignancy, prostate tumor volume was halved after 5 weeks of Paclitaxel/ATL1101 combination treatment, compared with control Paclitaxel treated mice.

Other Posts From Category "gear":

Related Posts